Immedica Pharma Ab
Clinical trials sponsored by Immedica Pharma Ab, explained in plain language.
-
Can an enzyme replacement tame a rare metabolic disorder?
Disease control CompletedThis phase 3 trial is testing whether pegzilarginase, an enzyme replacement therapy, can lower plasma arginine levels and improve mobility in children and adults with arginase 1 deficiency, a rare genetic condition that causes high arginine levels and neurological problems. Parti…
Phase 3 • Sponsor: Immedica Pharma AB • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Can a modified enzyme starve Hard-to-Treat blood cancers?
Disease control CompletedThis phase 1 trial is testing an investigational drug called AEB1102 in adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has returned or stopped responding to standard treatments. AEB1102 is a modified human enzyme that breaks down arginine, an amin…
Phase 1 • Sponsor: Immedica Pharma AB • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a new drug tame advanced solid tumors?
Disease control CompletedThis early-stage trial is testing an experimental drug called AEB1102 in people with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The main goal is to find the highest dose that is safe and to understand the drug's…
Phase 1 • Sponsor: Immedica Pharma AB • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New hormone treatment shows promise for rare adrenal disorder
Disease control CompletedThis study looked at the long-term safety of a medication called Chronocort in 76 people aged 16 and older with congenital adrenal hyperplasia (CAH), a condition where the body can't make enough cortisol. Researchers monitored for signs of over- or under-treatment, adrenal crises…
Phase 3 • Sponsor: Immedica Pharma AB • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for babies with rare enzyme disorder: weekly shot shows promise
Disease control CompletedThis study tested a weekly injection of pegzilarginase (Loargys) in 3 infants under 24 months old with arginase 1 deficiency, a rare genetic disorder that causes harmful buildup of arginine. The goal was to see if the drug is safe and can lower arginine levels in the blood. The t…
Phase 3 • Sponsor: Immedica Pharma AB • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC